The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global artificial cornea and corneal implant market reached a value of US$ 385.5 Million in 2021. Looking forward, IMARC Group expects the market to reach US$ 605 Million by 2027, exhibiting at a CAGR of 7.10% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Artificial cornea and corneal implant refer to the surgical procedure conducted to replace parts of the damaged cornea with healthy corneal tissue obtained from a donor. The procedures are usually performed for the treatment of keratoconus, infectious keratitis, corneal ulcers and Fuchs dystrophy diseases. They include various medical procedures, such as penetrating and endothelial keratoplasty, that involve the transplantation of entire corneal stem cells. The implants are commonly available in synthetic and biosynthetic variants, which are manufactured using recombinant collagen and chemical substances. The implant procedures aid in restoring vision, relieving pain and treating damaged corneas. As a result, these procedures are widely conducted in hospitals and ophthalmic and ambulatory surgical centers (ASCs).
The increasing prevalence of corneal infections and eye-related disorders among the masses is one of the key factors driving the growth of the market. Moreover, the rising geriatric population, which is more susceptible to such ailments, is providing a thrust to the market growth. Artificial cornea and corneal implant procedures are extensively used for the timely treatment of these disorders and the prevention of corneal blindness. Additionally, the increasing preference for penetrating keratoplasty procedures is favoring the market growth. These surgical procedures involve full-thickness corneal transplantation, which aids in treating ecstatic corneal diseases, such as keratoconus and pellucid marginal degeneration. Various product innovations, such as the development of three-dimensional (3D) printed artificial corneas with enhanced biocompatibility and customizability, are contributing to the market growth. In line with this, the increasing demand for artificial cornea and corneal implants to treat cloudy cornea caused by prolonged exposure to screen times is positively impacting the market growth. Other factors, including significant improvements in the healthcare infrastructure, along with the implementation of various government initiatives to prevent visual impairment among the masses, are anticipated to drive the market toward growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global artificial cornea and corneal implant market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, transplant type, disease indication and end user.
Breakup by Type:
Breakup by Transplant Type:
Breakup by Disease Indication:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Advancing Sight Network, AJL Ophthalmic S.A., Aurolab, Corneat Vision Ltd, EyeYon Medical, Florida Lions Eye Bank, Keramed Inc., L V Prasad Eye Institute, LinkoCare Life Sciences AB, Mediphacos, Presbia PLC and San Diego Eye Bank.
|Base Year of the Analysis||2021|
|Segment Coverage||Type, Transplant Type, Disease Indication, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Advancing Sight Network, AJL Ophthalmic S.A., Aurolab, Corneat Vision Ltd, EyeYon Medical, Florida Lions Eye Bank, Keramed Inc., L V Prasad Eye Institute, LinkoCare Life Sciences AB, Mediphacos, Presbia PLC and San Diego Eye Bank.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at